Workflow
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
ALECAlector(ALEC) GlobeNewswire·2025-01-13 13:00

Clinical Pipeline Progress - The pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN is ongoing, with topline data expected by Q4 2025 [1][4] - The PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease has reached approximately 75% of its target enrollment, with full enrollment anticipated by mid-2025 [1][9] - Latozinemab has been granted Orphan Drug, Breakthrough Therapy, and Fast Track designations, positioning it as the most advanced PGRN-elevating candidate for FTD-GRN [4] Preclinical and Research Pipeline - The company is advancing multiple preclinical programs leveraging its Alector Brain Carrier (ABC) technology, including ADP037-ABC (anti-amyloid beta antibody for Alzheimer's), ADP050-ABC (GCase replacement therapy for Parkinson's and Lewy body dementia), and ADP063-ABC/ADP064-ABC (tau-blocking therapeutic candidates) [1][5][9] - ADP056, a reelin modulator, is designed to block tau pathology and promote synaptic function in Alzheimer's disease [9] - The ABC platform aims to enhance therapeutic delivery to the brain, potentially enabling lower doses, subcutaneous delivery, and reduced treatment costs [1][7][9] Financial Position and Strategic Priorities - As of September 30, 2024, the company had 457.2millionincash,cashequivalents,andinvestments,expectedtofundoperationsthrough2026[1][6]−Thecompanyisfocusedonadvancingitsclinicalandpreclinicalpipeline,withkeymilestonesexpectedin2025,includingtheINFRONT−3toplinedatareadoutandcompletionofPROGRESS−ADenrollment[1][4][9]CollaborationsandGrants−ThecompanyiscollaboratingwithGSKonthedevelopmentofprogranulinprograms,includinglatozinemabandAL101/GSK4527226[2][9]−InDecember2024,thecompanyandtheUniversityofLuxembourgwereawardeda457.2 million in cash, cash equivalents, and investments, expected to fund operations through 2026 [1][6] - The company is focused on advancing its clinical and preclinical pipeline, with key milestones expected in 2025, including the INFRONT-3 topline data readout and completion of PROGRESS-AD enrollment [1][4][9] Collaborations and Grants - The company is collaborating with GSK on the development of progranulin programs, including latozinemab and AL101/GSK4527226 [2][9] - In December 2024, the company and the University of Luxembourg were awarded a 1.7 million grant from The Michael J. Fox Foundation for Parkinson's Research to advance the ADP027-ABC program targeting GPNMB for Parkinson's disease [9]